<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00192504</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP106</org_study_id>
    <nct_id>NCT00192504</nct_id>
  </id_info>
  <brief_title>Safety Study of a Monoclonal Antibody to Respiratory Syncytial Virus (RSV) in Children Hospitalized With RSV Infection</brief_title>
  <official_title>A Phase 1, Randomized, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Single Intravenous Dose of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody to Respiratory Syncytial Virus (RSV), in Otherwise Healthy Children Hospitalized With RSV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety of motavizumab (MEDI-524) following a&#xD;
      single intravenous dose in children hospitalized with respiratory syncytial virus (RSV).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was designed as a Phase 1, randomized, double-blind, placebo-controlled,&#xD;
      dose-escalation, multicenter clinical study to evaluate the safety, tolerability, serum&#xD;
      concentrations, and immunogenicity of a single intravenous dose of motavizumab (MEDI-524) and&#xD;
      the effect on the amount of respirtory syncytial virus (RSV) in the respiratory tract&#xD;
      (nasopharynx) of otherwise healthy children hospitalized with RSV infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Reporting Adverse Events Through 30 Days After Dosing</measure>
    <time_frame>From the start of treatment to 30 days after dosing</time_frame>
    <description>Safety and tolerability of motavizumab (MEDI-524) was measured by adverse events through 30 days after dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events Through 30 Days After Dosing</measure>
    <time_frame>From the start of treatment to 30 days after dosing</time_frame>
    <description>Safety and tolerability of motavizumab (MEDI-524) was measured by serious adverse events through 30 days after dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Occurrence of Increased Toxixity Grade From Baseline as Determined by Laboratory Evaluations</measure>
    <time_frame>From the start of treatment to 30 days after dosing</time_frame>
    <description>Safety and tolerability of motavizumab (MEDI-524) was measured by the occurrence of increased toxicity grade from baseline as determined by laboratory evaluations (complete blood count, aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), creatinine, and urinalysis) at baseline and at each study collection time point following dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To Describe the Mean Trough Serum Concentrations of Motavizumab (MEDI-524) Administered as a Single Intravenous Dose at Day 2 and Day 30</measure>
    <time_frame>Day 2 and Day 30</time_frame>
    <description>Mean trough serum concentrations of motavizumab (MEDI-524) were collected on Day 2 and on Day 30. Serum concentrations of MEDI-524 were analysed using a qualified enzyme-linked immunosorbent assay (ELISA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Describe the Immunogenicity of Motavizumab (MEDI-524) Following a Single IV Dose at Day 0</measure>
    <time_frame>Immediately before dosing on Day 0</time_frame>
    <description>The serum anti-motavizumab antibody titers were measured in subjects on Day 0 (before dosing). Anti-motavizumab antibody assays were performed at MedImmune using a qualified assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Describe the Immunogenicity of Motavizumab (MEDI-524) Following a Single IV Dose at Day 30</measure>
    <time_frame>Day 30</time_frame>
    <description>The serum anti-motavizumab antibody titers were measured in subjects on Day 30. Anti-motavizumab antibody assays were performed at MedImmune using a qualified assay.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Respiratory Syncytial Virus Prophylaxis</condition>
  <arm_group>
    <arm_group_label>Motavizumab, 3 mg/kg as a single intravenous dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Motavizumab, 3 mg/kg as a single intravenous dose administered on Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Motavizumab, 15 mg/kg as a single intravenous dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Motavizumab, 15 mg/kg as a single intravenous dose administered on Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Motavizumab, 30 mg/kg as a single intravenous dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Motavizumab, 30 mg/kg as a single intravenous dose administered on Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, as a single intravenous dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, as a single intravenous dose administered on Day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Motavizumab</intervention_name>
    <description>Single dose of Motavizumab at a dose of 3 mg/kg administered intravenously (in the vein) on Day 0</description>
    <arm_group_label>Motavizumab, 3 mg/kg as a single intravenous dose</arm_group_label>
    <other_name>MEDI-524</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Motavizumab</intervention_name>
    <description>Single dose of Motavizumab at a dose of 15 mg/kg administered intravenously (in the vein) on Day 0</description>
    <arm_group_label>Motavizumab, 15 mg/kg as a single intravenous dose</arm_group_label>
    <other_name>MEDI-524</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Motavizumab</intervention_name>
    <description>Single dose of Motavizumab at a dose of 30 mg/kg administered intravenously (in the vein) on Day 0</description>
    <arm_group_label>Motavizumab, 30 mg/kg as a single intravenous dose</arm_group_label>
    <other_name>MEDI-524</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose of placebo administered intravenously (in the vein) on Day 0</description>
    <arm_group_label>Placebo, as a single intravenous dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previously healthy&#xD;
&#xD;
          -  Age 24 months and younger at the time of randomization&#xD;
&#xD;
          -  Gestational age of 36 weeks gestation and older&#xD;
&#xD;
          -  Randomization within 24 hours after hospitalization&#xD;
&#xD;
          -  Hospitalized for lower respiratory tract illness (ie, respiratory syncytial virus&#xD;
             (RSV) bronchiolitis and/or pneumonia) documented by positive RSV antigen detection or&#xD;
             culture in respiratory secretions within 72 hours before randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Already received or would receive ribavirin or other anti-viral treatment for the&#xD;
             current episode of RSV infection prior to randomization&#xD;
&#xD;
          -  Required intubation for ventilatory support&#xD;
&#xD;
          -  Any medically significant underlying ongoing chronic illness or organ system&#xD;
             dysfunction or other known acute illness, other than RSV infection&#xD;
&#xD;
          -  Known renal impairment, hepatic dysfunction, hematologic abnormalities, seizure or&#xD;
             other neurologic disorder or immunodeficiency&#xD;
&#xD;
          -  Requirement for supplemental oxygen at any time prior to the current RSV infection&#xD;
             (brief use of oxygen in the immediate postnatal period to treat a transient condition&#xD;
             was allowed)&#xD;
&#xD;
          -  Mechanical ventilation at any time prior to the onset of the current RSV infection&#xD;
&#xD;
          -  Congenital heart disease (children with medically or surgically corrected patent&#xD;
             ductus arteriosus [PDA], small atrial septal defect [ASD] or ventricular septal defect&#xD;
             [VSD] were allowed)&#xD;
&#xD;
          -  Previous reaction to intravneous immunoglobulin (IVIG), blood products, or other&#xD;
             foreign proteins&#xD;
&#xD;
          -  Prior use of IVIG, RSV-IGIV (RespiGam), palivizumab (Synagis), or other immunoglobulin&#xD;
             products within the past 2 months&#xD;
&#xD;
          -  Currently receiving other investigational agents or have received any other&#xD;
             investigational agents within the last 3 months&#xD;
&#xD;
          -  Prior or current participation in any investigational study with a therapeutic agent&#xD;
             or vaccine for RSV&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Genevieve A Losonsky, MD</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <verification_date>October 2006</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <results_first_submitted>September 10, 2021</results_first_submitted>
  <results_first_submitted_qc>September 10, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 8, 2021</results_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <name_title>Genevieve A. Losonsky, MD/Vice President, Clinical Development</name_title>
    <organization>MedImmune, LLC</organization>
  </responsible_party>
  <keyword>MEDI-524</keyword>
  <keyword>Motavizumab</keyword>
  <keyword>respiratory syncytial virus</keyword>
  <keyword>children</keyword>
  <keyword>intravenous</keyword>
  <keyword>Rezield</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The screening period occurred within 24 hours before randomization. All subjects who were screened were randomized into the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Motavizumab (MEDI-524), 3 mg/kg</title>
          <description>Motavizumab, 3 mg/kg as a single intravenous dose administered on Day 0</description>
        </group>
        <group group_id="P2">
          <title>Motavizumab (MEDI-524), 15 mg/kg</title>
          <description>Motavizumab, 15 mg/kg as a single intravenous dose administered on Day 0</description>
        </group>
        <group group_id="P3">
          <title>Motavizumab (MEDI-524), 30 mg/kg</title>
          <description>Motavizumab, 30 mg/kg as a single intravenous dose administered on Day 0</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo, as a single intravenous dose administered on Day 0</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6">Baseline demographics are not available on one patient who did not receive study drug.</participants>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Dosing window missed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Motavizumab (MEDI-524), 3 mg/kg</title>
          <description>Motavizumab, 3 mg/kg as a single intravenous dose administered on Day 0</description>
        </group>
        <group group_id="B2">
          <title>Motavizumab (MEDI-524), 15 mg/kg</title>
          <description>Motavizumab, 15 mg/kg as a single intravenous dose administered on Day 0</description>
        </group>
        <group group_id="B3">
          <title>Motavizumab (MEDI-524), 30 mg/kg</title>
          <description>Motavizumab, 30 mg/kg as a single intravenous dose administered on Day 0</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo, as a single intravenous dose administered on Day 0</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="15"/>
            <count group_id="B5" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age at randomization</description>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.84" spread="6.62"/>
                    <measurement group_id="B2" value="3.18" spread="1.56"/>
                    <measurement group_id="B3" value="10.78" spread="9.07"/>
                    <measurement group_id="B4" value="7.43" spread="7.69"/>
                    <measurement group_id="B5" value="7.51" spread="7.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Baseline demographics are not available for one patient in the 30 mg/kg group because the patient received no study drug in the study.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White/Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.728" spread="1.392"/>
                    <measurement group_id="B2" value="5.516" spread="0.891"/>
                    <measurement group_id="B3" value="9.194" spread="3.43"/>
                    <measurement group_id="B4" value="7.386" spread="3.218"/>
                    <measurement group_id="B5" value="7.599" spread="2.903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Adverse Events Through 30 Days After Dosing</title>
        <description>Safety and tolerability of motavizumab (MEDI-524) was measured by adverse events through 30 days after dosing</description>
        <time_frame>From the start of treatment to 30 days after dosing</time_frame>
        <population>All patients who recieved study drug were included in the analysis of safety.</population>
        <group_list>
          <group group_id="O1">
            <title>Motavizumab (MEDI-524), 3 mg/kg</title>
            <description>Motavizumab, 3 mg/kg as a single intravenous dose administered on Day 0</description>
          </group>
          <group group_id="O2">
            <title>Motavizumab (MEDI-524), 15 mg/kg</title>
            <description>Motavizumab, 15 mg/kg as a single intravenous dose administered on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Motavizumab (MEDI-524), 30 mg/kg</title>
            <description>Motavizumab, 30 mg/kg as a single intravenous dose administered on Day 0</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo, as a single intravenous dose administered on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Adverse Events Through 30 Days After Dosing</title>
          <description>Safety and tolerability of motavizumab (MEDI-524) was measured by adverse events through 30 days after dosing</description>
          <population>All patients who recieved study drug were included in the analysis of safety.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Serious Adverse Events Through 30 Days After Dosing</title>
        <description>Safety and tolerability of motavizumab (MEDI-524) was measured by serious adverse events through 30 days after dosing</description>
        <time_frame>From the start of treatment to 30 days after dosing</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Motavizumab (MEDI-524), 3 mg/kg</title>
            <description>Motavizumab, 3 mg/kg as a single intravenous dose administered on Day 0</description>
          </group>
          <group group_id="O2">
            <title>Motavizumab (MEDI-524), 15 mg/kg</title>
            <description>Motavizumab, 15 mg/kg as a single intravenous dose administered on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Motavizumab (MEDI-524), 30 mg/kg</title>
            <description>Motavizumab, 30 mg/kg as a single intravenous dose administered on Day 0</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo, as a single intravenous dose administered on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Serious Adverse Events Through 30 Days After Dosing</title>
          <description>Safety and tolerability of motavizumab (MEDI-524) was measured by serious adverse events through 30 days after dosing</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Describe the Immunogenicity of Motavizumab (MEDI-524) Following a Single IV Dose at Day 0</title>
        <description>The serum anti-motavizumab antibody titers were measured in subjects on Day 0 (before dosing). Anti-motavizumab antibody assays were performed at MedImmune using a qualified assay.</description>
        <time_frame>Immediately before dosing on Day 0</time_frame>
        <population>All patients who received a full dose of study drug were included in the analysis of immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Motavizumab (MEDI-524), 3 mg/kg</title>
            <description>Motavizumab, 3 mg/kg as a single intravenous dose administered on Day 0</description>
          </group>
          <group group_id="O2">
            <title>Motavizumab (MEDI-524), 15 mg/kg</title>
            <description>Motavizumab, 15 mg/kg as a single intravenous dose administered on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Motavizumab (MEDI-524), 30 mg/kg</title>
            <description>Motavizumab, 30 mg/kg as a single intravenous dose administered on Day 0</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo, as a single intravenous dose administered on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>To Describe the Immunogenicity of Motavizumab (MEDI-524) Following a Single IV Dose at Day 0</title>
          <description>The serum anti-motavizumab antibody titers were measured in subjects on Day 0 (before dosing). Anti-motavizumab antibody assays were performed at MedImmune using a qualified assay.</description>
          <population>All patients who received a full dose of study drug were included in the analysis of immunogenicity.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Describe the Immunogenicity of Motavizumab (MEDI-524) Following a Single IV Dose at Day 30</title>
        <description>The serum anti-motavizumab antibody titers were measured in subjects on Day 30. Anti-motavizumab antibody assays were performed at MedImmune using a qualified assay.</description>
        <time_frame>Day 30</time_frame>
        <population>All patients who received a full dose of study drug were included in the analysis of immunogenicity. One patient in the 3 mg/kg group was not assessed for immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Motavizumab (MEDI-524), 3 mg/kg</title>
            <description>Motavizumab, 3 mg/kg as a single intravenous dose administered on Day 0</description>
          </group>
          <group group_id="O2">
            <title>Motavizumab (MEDI-524), 15 mg/kg</title>
            <description>Motavizumab, 15 mg/kg as a single intravenous dose administered on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Motavizumab (MEDI-524), 30 mg/kg</title>
            <description>Motavizumab, 30 mg/kg as a single intravenous dose administered on Day 0</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo, as a single intravenous dose administered on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>To Describe the Immunogenicity of Motavizumab (MEDI-524) Following a Single IV Dose at Day 30</title>
          <description>The serum anti-motavizumab antibody titers were measured in subjects on Day 30. Anti-motavizumab antibody assays were performed at MedImmune using a qualified assay.</description>
          <population>All patients who received a full dose of study drug were included in the analysis of immunogenicity. One patient in the 3 mg/kg group was not assessed for immunogenicity.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Occurrence of Increased Toxixity Grade From Baseline as Determined by Laboratory Evaluations</title>
        <description>Safety and tolerability of motavizumab (MEDI-524) was measured by the occurrence of increased toxicity grade from baseline as determined by laboratory evaluations (complete blood count, aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), creatinine, and urinalysis) at baseline and at each study collection time point following dosing</description>
        <time_frame>From the start of treatment to 30 days after dosing</time_frame>
        <population>All patients who recieved study drug were included in the analysis of safety.</population>
        <group_list>
          <group group_id="O1">
            <title>Motavizumab (MEDI-524), 3 mg/kg</title>
            <description>Motavizumab, 3 mg/kg as a single intravenous dose administered on Day 0</description>
          </group>
          <group group_id="O2">
            <title>Motavizumab (MEDI-524), 15 mg/kg</title>
            <description>Motavizumab, 15 mg/kg as a single intravenous dose administered on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Motavizumab (MEDI-524), 30 mg/kg</title>
            <description>Motavizumab, 30 mg/kg as a single intravenous dose administered on Day 0</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo, as a single intravenous dose administered on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>The Occurrence of Increased Toxixity Grade From Baseline as Determined by Laboratory Evaluations</title>
          <description>Safety and tolerability of motavizumab (MEDI-524) was measured by the occurrence of increased toxicity grade from baseline as determined by laboratory evaluations (complete blood count, aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), creatinine, and urinalysis) at baseline and at each study collection time point following dosing</description>
          <population>All patients who recieved study drug were included in the analysis of safety.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>To Describe the Mean Trough Serum Concentrations of Motavizumab (MEDI-524) Administered as a Single Intravenous Dose at Day 2 and Day 30</title>
        <description>Mean trough serum concentrations of motavizumab (MEDI-524) were collected on Day 2 and on Day 30. Serum concentrations of MEDI-524 were analysed using a qualified enzyme-linked immunosorbent assay (ELISA).</description>
        <time_frame>Day 2 and Day 30</time_frame>
        <population>All patients who recieved a full dose of study drug were included in the analysis of trough serum concentrations. One patient in the 3 mg/kg group was not assessed for serum trough levels at either Day 2 or Day 30.</population>
        <group_list>
          <group group_id="O1">
            <title>Motavizumab (MEDI-524), 3 mg/kg</title>
            <description>Motavizumab, 3 mg/kg as a single intravenous dose administered on Day 0</description>
          </group>
          <group group_id="O2">
            <title>Motavizumab (MEDI-524), 15 mg/kg</title>
            <description>Motavizumab, 15 mg/kg as a single intravenous dose administered on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Motavizumab (MEDI-524), 30 mg/kg</title>
            <description>Motavizumab, 30 mg/kg as a single intravenous dose administered on Day 0</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo, as a single intravenous dose administered on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>To Describe the Mean Trough Serum Concentrations of Motavizumab (MEDI-524) Administered as a Single Intravenous Dose at Day 2 and Day 30</title>
          <description>Mean trough serum concentrations of motavizumab (MEDI-524) were collected on Day 2 and on Day 30. Serum concentrations of MEDI-524 were analysed using a qualified enzyme-linked immunosorbent assay (ELISA).</description>
          <population>All patients who recieved a full dose of study drug were included in the analysis of trough serum concentrations. One patient in the 3 mg/kg group was not assessed for serum trough levels at either Day 2 or Day 30.</population>
          <units>Micrograms per mililiter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Trough Serum Concentration at Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.78" spread="20.09"/>
                    <measurement group_id="O2" value="170.8" spread="38.43"/>
                    <measurement group_id="O3" value="333.2" spread="99.86"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trough Serum Concentration at Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.63" spread="13.08"/>
                    <measurement group_id="O2" value="59.18" spread="12.72"/>
                    <measurement group_id="O3" value="80.28" spread="27.34"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time of the first administration of motavizumab (MEDI-524) to 30 days after dosing.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Motavizumab (MEDI-524), 3 mg/kg</title>
          <description>Motavizumab, 3 mg/kg as a single intravenous dose administered on Day 0</description>
        </group>
        <group group_id="E2">
          <title>Motavizumab (MEDI-524), 15 mg/kg</title>
          <description>Motavizumab, 15 mg/kg as a single intravenous dose administered on Day 0</description>
        </group>
        <group group_id="E3">
          <title>Motavizumab (MEDI-524), 30 mg/kg</title>
          <description>Motavizumab, 30 mg/kg as a single intravenous dose administered on Day 0</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo, as a single intravenous dose administered on Day 0</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Epstein-Barr virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Disbacteriosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Genital infection fungal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Haemophilus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pseudomonal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Superinfection bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Viral skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic respiratory symptom</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Heat rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Skin erosion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haemodynamic instability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Genevieve A. Losonsky, MD/VP Clinical Development</name_or_title>
      <organization>MedImmune, LLC</organization>
      <phone>301-398-0000</phone>
      <email>losonskyG@medimmune.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

